Register

Login

Vet Times logo
  • Register
  • Login
  • View all news
  • Vets news
  • Vet Nursing news
  • Business news
  • Podcasts
  • + Media
    • Videos
    • Podcasts
    • Crossword
  • View all clinical
  • Clinical hubs
  • Small animal
  • Livestock
  • Equine
  • Exotics
  • Job Seekers
  • Recruiters
  • Career Advice
About
Vet Times App
Contact Us
For Advertisers
NewsClinicalJobs

Search Articles & More

Vet Times logo

Vets

All Vets newsSmall animalLivestockEquineExoticWork and well-beingInternational

Vet Nursing

All Vet Nursing newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Business

All Business newsHuman resourcesBig 6SustainabilityFinanceDigitalPractice profilesPractice developments

Media

VideosPodcastsDigital EditionCrossword

The latest veterinary news, delivered straight to your inbox.

Choose which topics you want to hear about and how often.

Vet Times logo 2

About

The team

Vet Times App

Advertise with us

Recruitment

Contact us

Vet Times logo 2

Vets

All Vets news

Small animal

Livestock

Equine

Exotic

Work and well-being

International

Vet Nursing

All Vet Nursing news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Business

All Business news

Human resources

Big 6

Sustainability

Finance

Digital

Practice profiles

Practice developments

Clinical

All Clinical content

Clinical hubs

Small animal

Livestock

Equine

Exotics

Jobs

All Jobs content

Job Seekers

Recruiters

Career Advice

Media

All Media content

Videos

Podcasts

Digital Edition

Crossword


Terms and conditions

Complaints policy

Cookie policy

Privacy policy

fb-iconinsta-iconlinkedin-icontwitter-iconyoutube-icon

© Veterinary Business Development Ltd 2026

IPSO_regulated

18 Nov 2026

Early indicator of side effects from dog anaemia treatment identified

Early increases in alkaline phosphatase activity were associated with polydipsia two to three weeks later in dogs with immune-mediated haemolytic anaemia.

author_img

Chris Simpson

Job Title



Early indicator of side effects from dog anaemia treatment identified

A puppy with severe anaemia. Image: Todorean Gabriel / Adobe Stock

Fresh research from the RVC may offer vets insight into which dogs are at risk of side effects from treatments for a common autoimmune disease.

Scholars found that changes in a routinely measured blood enzyme in the liver, alkaline phosphatase (ALP), can offer an early indication into adverse side effects from immune-mediated haemolytic anaemia (IMHA).

In a study published in the scientific journal Plos One, academics investigated dynamic changes in clinicopathological variables as well as immune and glucocorticoid-regulated gene expression in dogs with IMHA.

Adverse effects

They sought to determine whether such changes are associated with quicker recovery from anaemia or the severity of treatment-related adverse effects. The researchers clinically monitored 29 client-owned dogs with non-associative IMHA, collecting residual blood samples at 0, 5, 21, 48 and 62 days after treatment at the RVC Queen Mother Hospital for Animals.

They found that several clinical and gene expression variables are “highly changeable” over time, providing what is said to be the first detailed picture of how these measures shift during the early treatment of IMHA.

They also explored how health-related quality of life was affected by treatment, finding treated dogs showed significant increases in bodyweight and body condition score over follow-up visits, whereas muscle condition score, non-invasive blood pressure and exercise tolerance did not change significantly across the same times.

However, none of the variables measured were associated with more rapid recovery from anaemia.

‘Important validation’

But they discovered that increasing ALP activity in the first five days following treatment was associated with excessive water intake at three weeks, suggesting early changes in glucocorticoid-response variables might be associated with severity of adverse effects later in the treatment timeline.

The authors noted: “This finding acts as important validation for our research approach because dogs possess a specific glucocorticoid-induced isoform of ALP that typically increases considerably when prednisolone treatment is initiated.

“Together, these preliminary results indicate that dynamic trends in widely available clinical tests could offer additional insight over static measures at diagnosis that have been evaluated previously as predictors of outcome in IMHA.”

Research call

The authors called for further research to explore the individualisation of immunosuppressive therapy for dogs with IMHA, describing ALP activity as a “key candidate” for investigation as a potential clinical tool for vets.

Author Barbara Glanemann, associate professor in small animal internal medicine at the RVC, said: “Our findings suggest commonly available laboratory changes early in treatment may help us all to better understand how an individual patient is responding and how high their risk is for developing adverse effects. This can help us to individualise our treatment strategies.”